利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.023 秒)

    Meningococcal vaccine based on lipooligosaccharide (LOS) originating from modified Neisseria meningitidis strains of immunotype L6
    4.
    发明授权
    Meningococcal vaccine based on lipooligosaccharide (LOS) originating from modified Neisseria meningitidis strains of immunotype L6 有权
    基于来自修饰的脑膜炎奈瑟氏球菌（LES）的脂多糖（LOS）的免疫型L6的脑膜炎球菌疫苗

    公开(公告)号：US09132181B2

    公开(公告)日：2015-09-15

    申请号：US12800454

    申请日：2010-05-14

    申请人： Noëlle Mistretta ,  Monique Moreau ,  Geneviève Renauld-Mongenie ,  Bachra Rokbi

    发明人： Noëlle Mistretta ,  Monique Moreau ,  Geneviève Renauld-Mongenie ,  Bachra Rokbi

    IPC分类号： A61K39/08 ,  A61K39/095

    CPC分类号： A61K31/739 ,  A61K9/127 ,  A61K39/095

    摘要： The invention especially relates to multivalent vaccine compositions that can treat or prevent at least 60, preferably 75% of infections caused by Neisseria meningitidis especially of serogroup B. To this end, the invention in particular provides a lipooligosaccharide (LOS) of N. meningitidis in particular constituted by a lipid A, an inner core, an α chain of L6 or L8 type, in which the heptose II residue of the inner core bears in position O-3 and in position O-6 or O-7 a phosphoethanolamine (PEA) substituent, and also to the construction of the strain of N. meningitidis that is capable of expressing such an LOS. The invention also relates to a strain of N. meningitidis of serogroup A that bears a lipooligosaccharide (LOS) in particular constituted by a lipid A, an inner core, an α chain of L6 type, in which the heptose II residue of the inner core bears in position O-3 a phosphoethanolamine (PEA) substituent and does not bear a PEA substituent in positions O-6 and O-7. The LOSs cited or originating from the mentioned strains may be used as vaccine antigens, especially in multivalent, e.g. divalent compositions, so as to offer protection against the major epidemiological complexes of N. meningitidis, especially of serogroup B.

    摘要翻译： 本发明特别涉及能够治疗或预防由脑膜炎奈瑟氏球菌特别是血清群B引起的至少60次，优选75％的感染的多价疫苗组合物。为此，本发明特别提供脑膜炎奈瑟球菌的低聚寡糖（LOS） 特别由脂质A，内核，L6或L8型的α链构成，其中内核的内酯II的残基在O-3位置和位置O-6或O-7是磷酸乙醇胺（PEA ）取代基，以及能够表达这种LOS的脑膜炎奈瑟氏球菌菌株的构建。 本发明还涉及一种血清群A的脑膜炎奈瑟氏球菌菌株，其具有特别由脂质A，内核，L6型α链构成的脂寡糖（LOS），其中内核的肝脏II残基 在O-3位置具有磷酸乙醇胺（PEA）取代基，并且在O-6和O-7位置不承担PEA取代基。 引用或源自所述菌株的LOS可以用作疫苗抗原，特别是多价的，例如， 二价成分，以保护脑膜炎奈瑟氏球菌，特别是血清群B的主要流行病学复合物。

    Meningococcal vaccine based on lipooligosaccharide (LOS) originating from modified Neisseria meningitidis strains of immunotype L6
    5.
    发明申请
    Meningococcal vaccine based on lipooligosaccharide (LOS) originating from modified Neisseria meningitidis strains of immunotype L6 审中-公开

    公开(公告)号：US20180036339A1

    公开(公告)日：2018-02-08

    申请号：US15584619

    申请日：2017-05-02

    申请人： Noelle Mistretta ,  Monique Moreau ,  Genevieve Renauld-Mongenie ,  Bachra Rokbi

    发明人： Noelle Mistretta ,  Monique Moreau ,  Genevieve Renauld-Mongenie ,  Bachra Rokbi

    IPC分类号： A61K31/739 ,  A61K9/127 ,  A61K39/095

    CPC分类号： A61K31/739 ,  A61K9/127 ,  A61K39/095

    摘要： The invention especially relates to multivalent vaccine compositions that can treat or prevent at least 60, preferably 75% of infections caused by Neisseria meningitidis especially of serogroup B. To this end, the invention in particular provides a lipooligosaccharide (LQS) of N. meningitidis in particular constituted by a lipid A, an inner core, an α chain of L6 or L8 type, in which the heptose II residue of the inner core bears in position O-3 and in position O-6 or O-7 a phosphoethanolamine (PEA) substituent, and also to the construction of the strain of N. meningitidis that is capable of expressing such an LOS. The invention also relates to a strain of N. meningitidis of serogroup A that bears a lipooligosaccharide (LOS) in particular constituted by a lipid A, an inner core, an α chain of L6 type, in which the heptose II residue of the inner core bears in position O-3 a phosphoethanolamine (PEA) substituent and does not bear a PEA substituent in positions O-6 and O-7. The LOSs cited or originating from the mentioned strains may be used as vaccine antigens, especially in multivalent, e.g. divalent compositions, so as to offer protection against the major epidemiological complexes of N. meningitidis, especially of scrogroup B.

    Meningococcal vaccine based on lipooligosaccharide (LOS) originating from modified Neisseria meningitidis strains of immunotype L6
    6.
    发明申请
    Meningococcal vaccine based on lipooligosaccharide (LOS) originating from modified Neisseria meningitidis strains of immunotype L6 有权
    基于来自修饰的脑膜炎奈瑟氏球菌（LES）的脂多糖（LOS）的免疫型L6的脑膜炎球菌疫苗

    公开(公告)号：US20100330160A1

    公开(公告)日：2010-12-30

    申请号：US12800454

    申请日：2010-05-14

    申请人： Noëlle Mistretta ,  Monique Moreau ,  Geneviève Renauld-Mongenie ,  Bachra Rokbi

    发明人： Noëlle Mistretta ,  Monique Moreau ,  Geneviève Renauld-Mongenie ,  Bachra Rokbi

    IPC分类号： A61K9/127 ,  A61P31/04 ,  C12N15/74 ,  C12N1/21 ,  C07H1/00 ,  C12P19/00 ,  A61K31/70

    CPC分类号： A61K31/739 ,  A61K9/127 ,  A61K39/095

    摘要： The invention especially relates to multivalent vaccine compositions that can treat or prevent at least 60, preferably 75% of infections caused by Neisseria meningitidis especially of serogroup B. To this end, the invention in particular provides a lipooligosaccharide (LOS) of N. meningitidis in particular constituted by a lipid A, an inner core, an α chain of L6 or L8 type, in which the heptose II residue of the inner core bears in position O-3 and in position O-6 or O-7 a phosphoethanolamine (PEA) substituent, and also to the construction of the strain of N. meningitidis that is capable of expressing such an LOS. The invention also relates to a strain of N. meningitidis of serogroup A that bears a lipooligosaccharide (LOS) in particular constituted by a lipid A, an inner core, an α chain of L6 type, in which the heptose II residue of the inner core bears in position O-3 a phosphoethanolamine (PEA) substituent and does not bear a PEA substituent in positions O-6 and O-7. The LOSs cited or originating from the mentioned strains may be used as vaccine antigens, especially in multivalent, e.g. divalent compositions, so as to offer protection against the major epidemiological complexes of N. meningitidis, especially of serogroup B.

    摘要翻译： 本发明特别涉及能够治疗或预防由脑膜炎奈瑟菌特别是血清群B引起的至少60次，优选75％的感染的多价疫苗组合物。为此，本发明特别提供脑膜炎奈瑟球菌的低聚寡糖（LOS） 特别由脂质A，内核，L6或L8型的α链构成，其中内核的内酯II的残基在O-3位置和位置O-6或O-7是磷酸乙醇胺（PEA ）取代基，以及能够表达这种LOS的脑膜炎奈瑟氏球菌菌株的构建。 本发明还涉及一种血清群A的脑膜炎奈瑟氏球菌菌株，其具有特别由脂质A，内核，L6型α链构成的脂寡糖（LOS），其中内核的肝脏II残基 在O-3位置具有磷酸乙醇胺（PEA）取代基，并且在O-6和O-7位置不承担PEA取代基。 引用或源自所述菌株的LOS可以用作疫苗抗原，特别是多价的，例如， 二价成分，以保护脑膜炎奈瑟氏球菌，特别是血清群B的主要流行病学复合物。

    Detoxification method for lipopolysaccharide (LPS) or lipid A of gram-negative bacteria
    7.
    发明申请
    Detoxification method for lipopolysaccharide (LPS) or lipid A of gram-negative bacteria 审中-公开
    革兰氏阴性细菌的脂多糖（LPS）或脂质A的解毒方法

    公开(公告)号：US20100291192A1

    公开(公告)日：2010-11-18

    申请号：US12800426

    申请日：2010-05-14

    申请人： Jean Haensler ,  François Dalençon ,  Monique Moreau ,  Noëlle Mistretta

    发明人： Jean Haensler ,  François Dalençon ,  Monique Moreau ,  Noëlle Mistretta

    IPC分类号： A61K39/02 ,  A61K35/74 ,  A61K9/127 ,  A61P31/04

    CPC分类号： A61K39/095 ,  A61K9/127 ,  A61K9/1272 ,  A61K39/02 ,  A61K39/39 ,  A61K2039/55555 ,  A61K2039/55572 ,  A61K2039/55583

    摘要： The invention relates to a method of detoxifying a lipopolysaccharide (LPS) or a lipid A from a Gram-negative bacterium, which comprises mixing the LPS or the lipid A with a cationic lipid so as to form a complex in which the LPS or the lipid A is associated with the cationic lipid. According to the conventional preparation modes, the cationic lipid with the co-lipid, if this latter is present, get(s) structured into complexes i.a. liposomes. When preparing lipidic complexes, the addition of LPS or Lipid A leads to an association of this latter with the cationic lipid and as a result, the LPS or lipid A is substantially detoxified. The LPS or lipid A detoxified by the complexes, e.g. when incorporated into liposomes, can be used as vaccinal antigen or as adjuvant.

    摘要翻译： 本发明涉及从革兰氏阴性细菌中解毒脂多糖（LPS）或脂质A的方法，其包括将LPS或脂质A与阳离子脂质混合以形成其中LPS或脂质 A与阳离子脂质有关。 根据常规的制备方式，具有共同脂质的阳离子脂质如果存在，则将其结构化成复合物。 脂质体。 当制备脂质复合物时，加入LPS或脂质A导致后者与阳离子脂质的结合，结果是LPS或脂质A基本上解毒。 由复合物解毒的LPS或脂质A，例如 当掺入脂质体时，可用作疫苗抗原或佐剂。

    Polymyxin B Analogs for LPS Detoxification
    8.
    发明申请
    Polymyxin B Analogs for LPS Detoxification 审中-公开
    多粘菌素B类似物用于LPS解毒

    公开(公告)号：US20090203881A1

    公开(公告)日：2009-08-13

    申请号：US12369983

    申请日：2009-02-12

    申请人： Massimo Porro ,  Massimo Velucchi ,  Alessandro Rustici ,  Monique Moreau ,  Noelle Mistretta ,  Tino Krell

    发明人： Massimo Porro ,  Massimo Velucchi ,  Alessandro Rustici ,  Monique Moreau ,  Noelle Mistretta ,  Tino Krell

    IPC分类号： C07K1/14

    CPC分类号： C07K7/08 ,  A61K38/00 ,  C07K7/06 ,  C07K7/54 ,  Y02A50/471 ,  Y02A50/473 ,  Y02A50/475 ,  Y02A50/478 ,  Y02A50/483

    摘要： The invention relates to SAEP II peptide dimers that mimic polymyxin B i.a. in its ability to bind non-covalently the lipopolysaccharide (LPS) of Gram-negative bacteria with high affinity, and therefore to detoxify LPS as polymyxin B does. The dimeric structure is maintained by a pair of disulphide bonds involving the two cystein residues present in the peptide sequence, which does not exceed 17 amino acids and essentially comprises cationic and hydrophobic amino acid residues. In the dimers of the invention, peptides may have a parallel or anti-parallel orientation. As a matter of example, a dimer of the invention is constituted by a peptide of formula NH2-Lys-Thr-Lys-Cys1-Lys-Phe-Leu-Leu-Leu-Cys2-COOH, either in a parallel or antiparallel dimeric form. SAEP II dimers are useful for treating or preventing septic shock and related disorders generated by Gram-negative bacteria infection. The invention also relates to LPS-peptide complexes in which LPS and SAEP II dimers are non-covalently bound together. These complexes are useful as vaccinal agents against Gram-negative bacteria infection.

    摘要翻译： 本发明涉及模拟多粘菌素B i.a.的SAEP II肽二聚体。 在其以高亲和力非共价结合革兰氏阴性细菌的脂多糖（LPS）的能力，因此使LPS作为多粘菌素B解毒。 二聚体结构通过涉及肽序列中存在的两个半胱氨酸残基的一对二硫键来维持，其不超过17个氨基酸并且基本上包含阳离子和疏水氨基酸残基。 在本发明的二聚体中，肽可以具有平行或反平行取向。 作为实例，本发明的二聚体由式NH2-Lys-Thr-Lys-Cys1-Lys-Phe-Leu-Leu-Leu-Leu-Cys2-COOH的肽构成，其平行或反向平行的二聚体形式 。 SAEP II二聚体可用于治疗或预防由革兰氏阴性菌感染引起的败血性休克和相关疾病。 本发明还涉及其中LPS和SAEP II二聚体非共价结合在一起的LPS-肽复合物。 这些复合物可用作抗革兰氏阴性菌感染的疫苗。

    Polymyxin B analogs for LPS detoxification
    9.
    发明授权
    Polymyxin B analogs for LPS detoxification 失效
    多粘菌素B类似物用于LPS解毒

    公开(公告)号：US07507718B2

    公开(公告)日：2009-03-24

    申请号：US11398915

    申请日：2006-04-06

    申请人： Massimo Porro ,  Massimo Velucchi ,  Alessandro Rustici ,  Monique Moreau ,  Noëlle Mistretta ,  Tino Krell

    发明人： Massimo Porro ,  Massimo Velucchi ,  Alessandro Rustici ,  Monique Moreau ,  Noëlle Mistretta ,  Tino Krell

    IPC分类号： A61K38/08 ,  A61K38/10

    CPC分类号： C07K7/08 ,  A61K38/00 ,  C07K7/06 ,  C07K7/54 ,  Y02A50/471 ,  Y02A50/473 ,  Y02A50/475 ,  Y02A50/478 ,  Y02A50/481 ,  Y02A50/483

    摘要： The invention relates to SAEP II peptide dimers that mimic polymyxin B i.a. in its ability to bind non-covalently the lipopolysaccharide (LPS) of Gram-negative bacteria with high affinity, and therefore to detoxify LPS. The dimeric structure is maintained by a pair of disulphide bonds between two cystein residues present in the peptide sequence, which does not exceed 17 amino acids and essentially comprises cationic and hydrophobic amino acid residues. The peptides in the dimers may have a parallel or anti-parallel orientation. SAEP II dimers are useful for treating or preventing septic shock and related disorders generated by Gram-negative bacteria infection. The invention also relates to LPS-peptide complexes in which LPS and SAEP II diners are non-covalently bound together. These complexes are useful as vaccinal agents against Gram-negative bacteria infection.

    摘要翻译： 本发明涉及模拟多粘菌素B i.a.的SAEP II肽二聚体。 在其以高亲和力非共价结合革兰氏阴性细菌的脂多糖（LPS）的能力，因此解毒LPS。 二聚体结构通过存在于肽序列中的两个半胱氨酸残基之间的一对二硫键保持，肽序列不超过17个氨基酸并且基本上包含阳离子和疏水氨基酸残基。 二聚体中的肽可以具有平行或反平行取向。 SAEP II二聚体可用于治疗或预防由革兰氏阴性菌感染引起的败血性休克和相关疾病。 本发明还涉及其中LPS和SAEP II食用者非共价结合在一起的LPS-肽复合物。 这些复合物可用作抗革兰氏阴性菌感染的疫苗。

    IgA1 protease fragment as carrier peptides
    10.
    发明授权
    IgA1 protease fragment as carrier peptides 失效
    IgA1蛋白酶片段作为载体肽

    公开(公告)号：US07235242B2

    公开(公告)日：2007-06-26

    申请号：US10841324

    申请日：2004-05-07

    申请人： Mark Achtman ,  Monique Moreau

    发明人： Mark Achtman ,  Monique Moreau

    IPC分类号： A61K39/00 ,  A61K39/02 ,  A61K39/12 ,  A61K39/385 ,  C07K1/00

    CPC分类号： A61K39/385 ,  A61K2039/6037 ,  C12N9/52

    摘要： The present invention is concerned with a fragment of IgA1-protease having 40 to 200 amino acid residues and comprising at least 40 amino acids of an amino acid sequence as shown in SEQ ID NO:1, beginning with the amino acid in any one of positions 1 to 5 and ending with an amino acid in any one of positions 40 to 104 or a homologous sequence, its use as a carrier for a conjugate, particularly in combination with a polysaccharide, and a process for producing the peptide as well as vaccines comprising said peptide.

    摘要翻译： 本发明涉及具有40-200个氨基酸残基的IgA1-蛋白酶的片段，并且包含SEQ ID NO：1所示的氨基酸序列的至少40个氨基酸，从任一位置的氨基酸开始 1至5并以40至104位任何一个氨基酸或同源序列结束，其作为缀合物的载体，特别是与多糖组合的用途，以及该肽的制备方法以及疫苗，其包含 所述肽。